Cargando…
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219469/ https://www.ncbi.nlm.nih.gov/pubmed/25105536 http://dx.doi.org/10.1038/bcj.2014.59 |
| _version_ | 1782342589614129152 |
|---|---|
| author | Cummins, K D Jane, S M Nikovic, S Bazargan, A Filshie, R Sutrave, G Hertzberg, M Scott, A Lane, S Yannakou, C K Ritchie, D D'Rozario, J Black, J Bavishi, K Wei, A |
| author_facet | Cummins, K D Jane, S M Nikovic, S Bazargan, A Filshie, R Sutrave, G Hertzberg, M Scott, A Lane, S Yannakou, C K Ritchie, D D'Rozario, J Black, J Bavishi, K Wei, A |
| author_sort | Cummins, K D |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4219469 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42194692014-11-04 Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia Cummins, K D Jane, S M Nikovic, S Bazargan, A Filshie, R Sutrave, G Hertzberg, M Scott, A Lane, S Yannakou, C K Ritchie, D D'Rozario, J Black, J Bavishi, K Wei, A Blood Cancer J Letter to the Editor Nature Publishing Group 2014-08 2014-08-08 /pmc/articles/PMC4219469/ /pubmed/25105536 http://dx.doi.org/10.1038/bcj.2014.59 Text en Copyright © 2014 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Cummins, K D Jane, S M Nikovic, S Bazargan, A Filshie, R Sutrave, G Hertzberg, M Scott, A Lane, S Yannakou, C K Ritchie, D D'Rozario, J Black, J Bavishi, K Wei, A Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia |
| title | Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia |
| title_full | Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia |
| title_fullStr | Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia |
| title_full_unstemmed | Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia |
| title_short | Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia |
| title_sort | sorafenib priming may augment salvage chemotherapy in relapsed and refractory flt3-itd-positive acute myeloid leukemia |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219469/ https://www.ncbi.nlm.nih.gov/pubmed/25105536 http://dx.doi.org/10.1038/bcj.2014.59 |
| work_keys_str_mv | AT cumminskd sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT janesm sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT nikovics sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT bazargana sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT filshier sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT sutraveg sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT hertzbergm sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT scotta sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT lanes sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT yannakouck sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT ritchied sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT drozarioj sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT blackj sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT bavishik sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia AT weia sorafenibprimingmayaugmentsalvagechemotherapyinrelapsedandrefractoryflt3itdpositiveacutemyeloidleukemia |